Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

NCT06401005 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.

NCT NCT06401005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06401005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
Lead sponsor
Hubei Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 28, 2024
Completion date
September 1, 2027
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer